CDC Merges Influenza, Coronavirus Divisions Into Unified Respiratory Unit
The federal agency restructured its flu and COVID-19 units into a unified Influenza and Respiratory Viruses Division (IRVD).
The federal agency restructured its flu and COVID-19 units into a unified Influenza and Respiratory Viruses Division (IRVD).
The federal agency restructured its flu and COVID-19 units into a unified Influenza and Respiratory Viruses Division (IRVD).
Read MoreLess than 44% of people in the US received a flu shot during the 2025-2026 season, down from 52% in 2021.
Read MoreA high-dose vaccine reduced hospital admissions for flu or pneumonia by nearly 9% among older individuals with chronic respiratory conditions like asthma and COPD.
Read MoreLeading medical societies warn that proposed changes and funding delays at the National Institutes of Health could disrupt active studies and patient care.
Read MoreAAP recommendations expand second-season RSV protection criteria for children ages 8 to 19 months, alongside updated infant COVID-19 vaccination recommendations.
Read MoreNew clinical recommendations emphasize the safety and importance of COVID-19, influenza, and RSV vaccines for individuals with weakened immune systems.
Read MorePreclinical studies on a new universal flu vaccine derived from baker’s yeast produced particles that provide broad protection against multiple influenza strains.
Read MoreResearchers have identified the first human case of swine influenza A(H1N2)v in mainland China, likely a domestic pig transmission to a rural child.
Read MoreThe National Foundation for Infectious Diseases (NFID) launched an initiative to streamline evidence-based information regarding respiratory disease prevention.
Read MoreThe American Academy of Pediatrics (AAP) issued updated recommendations for the prevention and control of influenza in children for the 2026-27 season, urging vaccination for all children aged 6 months and older.
Read MoreCo-Diagnostics submitted a dual 510(k) premarket notification and CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex respiratory test.
Read MoreThe FDA approved Moderna’s mFlusiva, the first seasonal influenza vaccine using mRNA technology to enter the US market.
Read MorePediatric influenza and Mycoplasma pneumoniae infections returned to pre-pandemic levels after COVID-19 restrictions were lifted.
Read MoreInfants exposed to viruses by older siblings face a higher risk of hospitalization and long-term socioeconomic challenges, according to new research.
Read MoreA study shows that a loss of immunity caused flu and RSV peaks to occur earlier in the season before returning to pre-pandemic patterns.
Read MoreSpecific host genotypes and sexes can cause influenza A viruses to gain virulence faster, potentially impacting the severity of flu outbreaks.
Read MoreParainfluenza virus activity is currently high across the US, while HMPV and rhinovirus/enterovirus levels are beginning to decline, according to the CDC.
Read MoreResearch suggests only 10 viral particles of the H5N1 bird flu are enough to cause a productive infection in dairy cows.
Read MoreThe AMDI Fast PCR System provides point-of-care results for RSV, influenza, and COVID-19 in less than 10 minutes.
Read MoreResearch involving 2.5 million patients found no increase in serious adverse events when receiving both COVID-19 and influenza vaccinations during the same visit.
Read MoreBacked by approximately $500 million in investment from Big Tech, the Intercept initiative will back broad-spectrum preventatives and air-cleaning technologies to reduce the global health burden of respiratory infections.
Read MoreThe FDA approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in patients 5 years of age and older.
Read MoreUnderlying chronic conditions and hospital transfers are major indicators of severe disease in pediatric patients with respiratory tract infections.
Read MoreResearchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Read More